Literature DB >> 26678334

Stemming Colorectal Cancer Growth and Metastasis: HOXA5 Forces Cancer Stem Cells to Differentiate.

Si Hui Tan1, Nick Barker2.   

Abstract

Wnt signaling drives colorectal cancer stem cells, but effective therapeutics targeting these cells and their signaling pathways are lacking. In this issue of Cancer Cell, Ordóñez-Morán and colleagues describe a promising therapeutic intervention for colorectal cancers that selectively induces cancer stem cell differentiation through HOXA5 expression and Wnt signaling inhibition.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26678334     DOI: 10.1016/j.ccell.2015.11.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  5 in total

1.  microRNA-26a-5p Promotes Proliferation and Migration of Osteosarcoma Cells by Targeting HOXA5 in vitro and in vivo.

Authors:  Tianhua Yu; Dexin Chen; Lei Zhang; Daqian Wan
Journal:  Onco Targets Ther       Date:  2019-12-30       Impact factor: 4.147

2.  A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer.

Authors:  Jinhua Wang; Yajing Xing; Yingying Wang; Yundong He; Liting Wang; Shihong Peng; Lianfang Yang; Jiuqing Xie; Xiaotao Li; Wenwei Qiu; Zhengfang Yi; Mingyao Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-10-22

3.  HOXA5 inhibits the proliferation of extrahepatic cholangiocarcinoma cells by enhancing MXD1 expression and activating the p53 pathway.

Authors:  Fei Xiong; Wenzheng Liu; Xin Wang; Guanhua Wu; Qi Wang; Tong Guo; Wenhua Huang; Bing Wang; Yongjun Chen
Journal:  Cell Death Dis       Date:  2022-09-27       Impact factor: 9.685

4.  Overexpression of HOXA10 promotes the growth and metastasis of nasopharyngeal carcinoma.

Authors:  Dan Gong; Hui Zhu; Lei Zeng; Ronghuan Hu; Jiali Hu; Jianwu Ding
Journal:  Exp Biol Med (Maywood)       Date:  2021-07-22

5.  Assessment of Expression of Homeobox A5 in Endometrial Cancer on the mRNA and Protein Level.

Authors:  Konrad Dziobek; Marcin Oplawski; Nikola Zmarzły; Beniamin O Gabarek; Robert Kiełbasiński; Kamil Kiełbasiński; Przemysław Kieszkowski; Karol Talkowski; Dariusz Boroń
Journal:  Curr Pharm Biotechnol       Date:  2020       Impact factor: 2.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.